Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$1.77 -4.3%	$1.23	$0.40 ▼ $1.85	$30.06M	0.19	306,004 shs	284,833 shs
DARE Daré Bioscience	$3.03 -2.9%	$2.96	$2.67 ▼ $5.76	$26.82M	1.2	36,360 shs	6,489 shs
MYNZ Mainz Biomed	$1.83 -8.0%	$2.62	$1.80 ▼ $26.56	$6.30M	0.31	131,769 shs	115,689 shs
VOR Vor Biopharma	$0.18 -13.3%	$0.40	$0.13 ▼ $1.80	$22.76M	-0.51	1.05 million shs	1.68 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	-4.32%	+14.94%	+21.23%	+174.04%	+106.37%
DARE Daré Bioscience	-2.88%	-5.31%	+4.84%	+5.21%	-42.74%
MYNZ Mainz Biomed	-8.04%	-11.81%	-19.38%	-58.03%	-93.11%
VOR Vor Biopharma	-12.03%	-18.63%	+6.49%	-79.66%	-85.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVC ABVC BioPharma	0.5844 of 5 stars	0.0	3.0	3.3	0.8	0.0
DARE Daré Bioscience	1.5597 of 5 stars	3.3	3.0	2.2	0.0	0.0
MYNZ Mainz Biomed	2.7608 of 5 stars	3.3	5.0	1.3	0.8	1.3
VOR Vor Biopharma	2.7894 of 5 stars	4.2	2.0	1.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	0.00	N/A	N/A	N/A
DARE Daré Bioscience	2.50	Moderate Buy	$12.00	296.04% Upside
MYNZ Mainz Biomed	2.50	Moderate Buy	$14.00	665.03% Upside
VOR Vor Biopharma	2.40	Hold	$7.06	3,775.42% Upside

Current Analyst Ratings Breakdown

Latest MYNZ, VOR, DARE, and ABVC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	VOR Vor Biopharma	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	VOR Vor Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform	$6.00 ➝ $6.00
5/9/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
5/8/2025	VOR Vor Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/8/2025	VOR Vor Biopharma	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/8/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Neutral	$7.00 ➝ $0.40
4/1/2025	DARE Daré Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
3/21/2025	VOR Vor Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
3/21/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.50 ➝ $13.00
3/21/2025	VOR Vor Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
3/20/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$7.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$508.38K	59.12	N/A	N/A	$1.02 per share	1.74
DARE Daré Bioscience	$25.91K	1,034.99	N/A	N/A	($0.61) per share	-4.97
MYNZ Mainz Biomed	$893.99K	7.04	N/A	N/A	$10.82 per share	0.17
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$10.52M	-$0.13	N/A	∞	N/A	-1,619.65%	-104.94%	-56.81%	8/12/2025 (Estimated)
DARE Daré Bioscience	-$30.16M	-$0.17	N/A	N/A	N/A	-191.65%	N/A	-18.98%	8/11/2025 (Estimated)
MYNZ Mainz Biomed	-$26.30M	-$65.60	N/A	N/A	N/A	N/A	N/A	N/A	7/1/2025 (Estimated)
VOR Vor Biopharma	N/A	-$1.51	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest MYNZ, VOR, DARE, and ABVC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/1/2025	N/A	MYNZ Mainz Biomed	-$2.80	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	DARE Daré Bioscience	-$0.63	-$0.50	+$0.13	-$0.50	$0.60 million	$0.03 million
4/30/2025	Q4 2024	ABVC ABVC BioPharma	N/A	-$0.06	N/A	-$0.06	N/A	N/A
4/15/2025	Q4 2024	ABVC ABVC BioPharma	N/A	$0.04	N/A	$0.04	N/A	N/A
3/31/2025	Q4 2024	DARE Daré Bioscience	-$0.66	-$0.64	+$0.02	-$0.64	$1.00 million	($0.06) million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
DARE Daré Bioscience	N/A	N/A	N/A	N/A	N/A
MYNZ Mainz Biomed	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.34	0.34
DARE Daré Bioscience	N/A	1.14	1.14
MYNZ Mainz Biomed	N/A	0.24	0.19
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
DARE Daré Bioscience	6.70%
MYNZ Mainz Biomed	N/A
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	17.10%
DARE Daré Bioscience	4.00%
MYNZ Mainz Biomed	18.20%
VOR Vor Biopharma	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	16.98 million	11.43 million	Not Optionable
DARE Daré Bioscience	30	8.85 million	8.35 million	Not Optionable
MYNZ Mainz Biomed	30	3.44 million	1.64 million	Not Optionable
VOR Vor Biopharma	140	124.96 million	65.45 million	Not Optionable

MYNZ, VOR, DARE, and ABVC Headlines

Recent News About These Companies

Vor Biopharma Inc. (NYSE:VOR) Receives $7.06 Average PT from Brokerages

June 13 at 1:33 AM | americanbankingnews.com

Vor Bio details extent of Cambridge layoffs in state filing

June 2, 2025 | bizjournals.com

Cambridge biotech company researching blood cancers to close, lay off 155

June 2, 2025 | masslive.com

Vor Biopharma Inc. Advanced Charts - Barron's

May 29, 2025 | barrons.com

RA Capital's biotech incubator lays off staffers: Stat

May 15, 2025 | fiercebiotech.com

Stifel cuts Vor Biopharma stock rating amid clinical and financial concerns

May 10, 2025 | investing.com

JMP Securities Downgrades Vor Biopharma (VOR)

May 10, 2025 | msn.com

Vor Biopharma draws downgrades on strategic review

May 9, 2025 | msn.com

Jones Trading cuts Vor Biopharma stock rating to Hold

May 9, 2025 | investing.com

HC Wainwright & Co. Downgrades Vor Biopharma (VOR)

May 9, 2025 | msn.com

4 more biotechs cut staff amid market tumult

May 9, 2025 | biopharmadive.com

Blood cancer biotech Vor Bio ends clinical work, lays off 95% of staff

May 8, 2025 | endpts.com

Vor Bio Winding Down Operations, Cutting Workforce, Exploring Potential Sale

May 8, 2025 | marketwatch.com

Vor Biopharma: Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

May 8, 2025 | finanznachrichten.de

Vor Biopharma stock plummets on operation wind-down

May 8, 2025 | in.investing.com

Vor Bio to wind down, halting cell therapy trials and shedding most staff

May 8, 2025 | fiercebiotech.com

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

May 8, 2025 | globenewswire.com

Vor Biopharma faces Nasdaq delisting over low stock price

April 27, 2025 | investing.com

Vor Bio price target lowered to $5 from $12 at Stifel

March 22, 2025 | markets.businessinsider.com

Vor Bio price target lowered to $13 from $17.50 at H.C. Wainwright

March 22, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
By Nathan Reiff | June 9, 2025
View 3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
Retail Investors Are Betting Big on Rocket Lab—Should You Too?
By Ryan Hasson | May 16, 2025
View Retail Investors Are Betting Big on Rocket Lab—Should You Too?
Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond?
By Thomas Hughes | May 22, 2025
View Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond?
Top 3 FOMO Stocks for 2025 With More Room to Run
By Dan Schmidt | June 9, 2025
View Top 3 FOMO Stocks for 2025 With More Room to Run

MYNZ, VOR, DARE, and ABVC Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$1.77 -0.08 (-4.32%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.80 +0.03 (+1.75%)

As of 06/13/2025 07:57 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Daré Bioscience NASDAQ:DARE

$3.03 -0.09 (-2.88%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.06 +0.04 (+1.16%)

As of 06/13/2025 04:04 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Mainz Biomed NASDAQ:MYNZ

$1.83 -0.16 (-8.04%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.84 +0.01 (+0.77%)

As of 06/13/2025 07:56 PM Eastern

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

Vor Biopharma NYSE:VOR

$0.18 -0.03 (-13.29%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.20 +0.01 (+7.63%)

As of 06/13/2025 07:45 PM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time